^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

curcumin/doxorubicin (iMX-110)

i
Other names: iMX-110, IMX-110, IMX110, IMX 110
Associations
Trials
Company:
Immix Biopharma
Drug class:
Angiogenesis inhibitor, STAT3 inhibitor, NF-κB inhibitor, Apoptosis inducer
Related drugs:
Associations
Trials
2ms
Cytotoxicity of Doxorubicin-Curcumin Nanoparticles Conjugated with Two Different Peptides (CKR and EVQ) against FLT3 Protein in Leukemic Stem Cells. (PubMed, Polymers (Basel))
Moreover, DCM-C + E and CM-C + E showed the highest toxicity in KG-1a and EoL-1 cells. Using two peptides likely improves the probability of micelles binding to the FLT3 receptor and induces cytotoxicity in leukemic stem cells.
Journal
|
FLT3 (Fms-related tyrosine kinase 3)
|
doxorubicin hydrochloride • curcumin/doxorubicin (iMX-110)
8ms
Curcumin attenuates doxorubicin-induced cardiotoxicity via suppressing oxidative Stress, preventing inflammation and apoptosis: Ultrastructural and computational approaches. (PubMed, Heliyon)
In cardiac tissue, CMN significantly increased the concentrations of SOD and CAT and significantly decreased the concentrations of MDA and TNF-α. Biochemical and histological studies have demonstrated that CMN has a heart-protective effect that might be related to its antioxidant and anti-inflammatory capabilities.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CAT (Catalase)
|
doxorubicin hydrochloride • curcumin/doxorubicin (iMX-110)
over1year
Clinical • P1/2 data • PK/PD data • Metastases
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
curcumin/doxorubicin (iMX-110)
over3years
The Target Differences of Anti-Tumorigenesis Potential of Curcumin and its Analogues Against HER-2 Positive and Triple-Negative Breast Cancer Cells. (PubMed, Adv Pharm Bull)
Overall, our study strengthens the potency of curcumin analogue, PGV-1, for treating several types of cancer, including metastatic breast cancer.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
HER-2 positive • HER-2 overexpression
|
curcumin/doxorubicin (iMX-110)
almost4years
Enhanced anticancer potency of doxorubicin in combination with curcumin in gastric adenocarcinoma. (PubMed, J Biochem Mol Toxicol)
Moreover, the anticancer activity of the Dox-Cur combination was significantly more than curcumin and doxorubicin treatments alone. According to the results, Dox-Cur combination therapy exerts more profound apoptotic and anticancer effects on the AGS cell line than curcumin or doxorubicin monotherapy.
Journal • Combination therapy • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BAX expression
|
doxorubicin hydrochloride • curcumin/doxorubicin (iMX-110)
4years
Liposomal Carrier Conjugated to APP-Derived Peptide for Brain Cancer Treatment. (PubMed, Cell Mol Neurobiol)
This drug-delivery liposomal carrier loaded with the anti-cancer compounds temozolomide (TMZ), curcumin, and doxorubicin crossed the BBB in an in vitro model as well as in vivo (mice model)...Treatment of mice that underwent intracranial injection of human U87 glioblastoma, with the targeted liposomes loaded with the three tested anti-cancer agents, delayed the tumor growth and prolonged the mice survival in a range of 45% -70%. It appears that the targeted liposomal drug-delivery system enables better therapeutic efficacy in a SCID mouse model of glioblastoma compared to the corresponding non-targeted liposomes and the free compounds.
Journal
|
APP (Amyloid Beta Precursor Protein)
|
temozolomide • doxorubicin hydrochloride • curcumin/doxorubicin (iMX-110)